期刊文献+

肿瘤坏死因子拮抗剂关节腔注射治疗强直性脊柱炎髋关节病变的临床研究 被引量:1

下载PDF
导出
摘要 目的观察髋关节腔注射益赛普治疗强直性脊柱炎髋关节病变的疗效及安全性。方法将符合标准的60例患者随机分为治疗组和对照组,治疗组采用在彩色多普勒高频探头引导下髋关节腔注射益赛普,对照组采用皮下注射益赛普,比较治疗前后BASRI、Harris髋关节评分、BASFI、BASDAI、ESR、CRP变化。结果两组治疗后Harris髋关节评分、BASFI、BASDAI、ESR和CRP均比治疗前显著降低(P〈0.05),治疗组优于对照组(P〈0.05);两组治疗前后BASRI未见显著改善。结论彩色多普勒高频探头引导下髋关节腔注射益赛普治疗强直性脊柱炎髋关节病变安全有效。
出处 《中外医学研究》 2010年第28期42-43,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
  • 相关文献

参考文献5

  • 1MacKay K,Brophy S,Mack C,et al.The development and valialion of a radiographic grading system for the hip in ankylosing spondylitis:the Bath ankylosing spondylitis radiology hip index.J Rheumatol,2000,27(12):2866-2872.
  • 2Mahomed NN,Amdt DC,McGrory BJ,et al.The Harris hip score:comparison of patient self-report with surgeon assessment.J Arthroplasty,2001,16(5):575.
  • 3Van der Cruyssen B,Ribbens C,Boonen A.The epidemiology of ankylosing spondylitis and the commencement of anti-TNF theraPy in daily rheumatology practice.Ann Rheum Dis,2007,66(8):1072-1077.
  • 4赵福涛 赵浩.益赛普治疗强直性脊柱炎的短期临床观察[J].中华风湿病学杂志,2008,12(3):50-51.
  • 5梁柳琴,詹钟平,杨岫岩,邱茜,许韩师,叶玉津.依那西普联合甲氨蝶呤对强直性脊柱炎髋关节病变的诱导与维持治疗初步探讨[J].中华风湿病学杂志,2008,12(9):591-593. 被引量:22

二级参考文献13

  • 1中华外科杂志编辑部.股骨头缺血性坏死专题讨论会纪要[J].中华外科杂志,1994,32:549-549.
  • 2Brophy S, Mackay K, Al-Saidi A, et al. The natural history of ankylosing spondylitis as defined by radiologieal progression. J Rheumatol, 2002, 29: 1236-1243.
  • 3Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for the New York criteria. Arthritis Rheum, 1984, 27: 361-368.
  • 4Mackay K, Brophy S , Mack C, et al. The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. J Rheumatol, 2000, 27: 2866-2872.
  • 5Russell AS, Orozco JH, Maksymowych WP.The dosage of infliximab in the treatment of ankyiosing spondylitis: dollars and sense. Clin Exp Rheumatol, 2002, 20 Suppl 28: S135-136.
  • 6Sidiropoulos P, Kritikos HD, Siakka P, el al. Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol, 2005, 23: 513-516.
  • 7Jois RN, Leeder J, Gibb A, et al. Low-dose infliximab treatment for ankylosing spondylitis clinically and cost effective. Rheumatology ( Oxford ), 2006, dS: 1566-1569.
  • 8Keeling S, Oswald A, Russell AS, et al. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year follow up. J Rheumatol, 2006, 33: 558-561.
  • 9Lee SH, Lee YA, Hong SJ, et al. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol, 2008, 27: 179-181.
  • 10Gadsby K, Deighton C. Charaeleristies and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosiug spondylitis. Rheumatology (Oxford), 2007, 46: 439-441.

共引文献21

同被引文献10

  • 1韩星海,赵福涛,管剑龙,刘彧,施冶青,戴生明,蔡青,赵东宝,孟济.局部X线放射治疗强直性脊柱炎髋关节病变的临床研究[J].中华风湿病学杂志,2005,9(1):8-11. 被引量:5
  • 2Brophy S,Mackay K,Al-Saidi A,et al.The natural history of ankylo-sing spondylitis as defined by radiological progression[J].Rheumatol,2002,29(6):1236-1243.
  • 3Maksymowyeh WP,Poole AR,Hiebert L,et al.Etanercepl exertsbene-ficial effects on articular cartilage biomarkers of degradation and turn-over in patients with ankylosing spondylitis[J].Rheumatol,2005,32(10):1911-1917.
  • 4Mahomed NN,Amdt DC,McGmry BJ,et al.The Harris hip score:com-parison of patient self-report with surgeon assessment[J].J Arthroplas-ty,2001,16(5):575.
  • 5Van der Cruyssen B,Ribbens C,Boonen A.The epidemiology of anky-losing spondylitis and the commencement of anti-TNF therapy in dailyrheumatology practice[J].Ann Rheum Dis,2007,66(8):1072-1077.
  • 6J Rumiantseva 0,Bochkova A,Loginova E,et al.Effects of infliximabon coxitis in patients with ankylosing spondylitis[J].Ann Rheum Dis,2008,67(SupplⅡ):516.
  • 7Xenofon Baraliakos,Juergen Braun.Hip involvement in ankylosingspondylitis[J].Rheumatology,2010,49(1):3-4.
  • 8Bert Vander Cruyssen,Elisa Munoz-Gomariz,Pilar Font,et al.Hip in-volvement in ankylosing spondylitis:epidemiology and risk factors as-sociated with hip replacement surgery[J].Rheumatology,2010,49(1):73-81.
  • 9梁柳琴,詹钟平,杨岫岩,邱茜,许韩师,叶玉津.依那西普联合甲氨蝶呤对强直性脊柱炎髋关节病变的诱导与维持治疗初步探讨[J].中华风湿病学杂志,2008,12(9):591-593. 被引量:22
  • 10马丽,王冬雪,吴东海.依那西普对难治眭强直性脊柱炎相关髋关节病变治疗的临床疗效观察[J].中华风湿病学杂志,2009,13(11):754-756. 被引量:11

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部